Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

UT Southwestern

Neither a doctor nor a teaching hospital

Research payments

$3,632,626

141 payments

Through program year 2025, UT Southwestern is reported as receiving $3,632,626 in research payments, across 141 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,023,258 2
2024 Research $79,996 14
2023 Research $54,062 10
2022 Research $58,085 1
2021 Research $41,635 17
2020 Research $108,550 10
2019 Research $2,267,040 87

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $1,940,283 81 payments
  2. Roche Diagnostics Corporation $1,485,325 4 payments
  3. Boehringer Ingelheim International GmbH $58,046 4 payments
  4. Amgen Inc. $52,772 2 payments
  5. Mallinckrodt Enterprises LLC $35,406 2 payments
  6. AstraZeneca Pharmaceuticals LP $15,728 8 payments
  7. AbbVie, Inc. $14,300 1 payment
  8. Philips Electronics North America Corporation $12,000 2 payments
  9. Ipsen Biopharmaceuticals, Inc $8,836 4 payments
  10. AstraZeneca UK Limited $3,720 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Rd004081 $1,425,485 1 payment
  2. A Multicenter Phase I,Ib Dose Escalation Study of WTX 124 as Monotherapy and in Combination with Pembrolizumab in Patients with Selected Advanced or Metastatic Solid Tumors $1,022,400 1 payment
  3. A Phase II Study of Pembrolizumab and Bavituximab in Patients with Advanced Hepatocellular Carcinoma $519,134 7 payments
  4. A Phase II Study of Pembrolizumab and Bavituximab in Patients with Advanced Hepatocellular Carcinoma $168,159 2 payments
  5. Reversal of Neuromuscular Blockade in Patients with Severe Renal Impairment $90,355 2 payments
  6. Rd002593 $59,840 3 payments
  7. A Phase I,II Study of Pembrolizumab MK-3475 in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma KEYNOTE-051 $54,262 2 payments
  8. A Phase 2b open-label, single-arm trial to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at-risk of developing CMV infection and,or disease following allogeneic haematopoietic stem cell transplantation HSCT $41,594 4 payments
  9. AMG 510 Ph1b Master Protocol 20190135 $39,744 1 payment
  10. Obesity Long term safety in patients with CV risk $37,734 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record